THOMAS R BUROKER DO NPI 1982665337

NPI Details

Thomas R Buroker, DO is a medical oncology internal medicine in Ankeny, IA with 58 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Thomas R Buroker, DO NPI is 1982665337. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

1950 SW MAGAZINE RD
ANKENY, IA
ZIP 50023-977
Phone: (515) 282-2921
Fax: (515) 282-1035

The NPI 1982665337 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, durvalumab, 10 mg (HCPCS:J9173)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1561)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, rituximab 10 mg and hyaluronidase (HCPCS:J9311)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg (HCPCS:Q5112)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Magnesium level (HCPCS:83735)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or (HCPCS:G2212)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)

The enumeration date for this NPI number is 3/28/2006 and was last updated on 11/17/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: